Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Altimmune management will host a conference call at
|Conference Call Information:
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Investor and Media Contact:
Chief Financial Officer
Source: Altimmune, Inc